NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

As they prepare for Phase One clinical trials, Corsair Pharma is prioritizing safety, tolerability, and quality at every stage of development. To support these critical goals, the company has ...

Having finally won US marketing approval, Cyclopharm has signed up the nation's biggest private and public hospital groups.

The LungFit PH device was approved ini 2022 by the U.S. Food and Drug Administration and the European Union to treat PPHN.

No significant causal relationship was identified between PAH and thyroid, lung, gastric, or colorectal cancers.

In a report released on January 24, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Insmed (INSM – Research Report), with a ...

Researchers from the University of Pittsburgh School of Medicine have linked pulmonary arterial hypertension (PAH), a ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

An imaging technique called 18F-FAPI PET may be able to detect early signs of changes in blood vessel tissues in PAH, a new ...

Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.

FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...